Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-12-06

Clinical Trial Update: A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of odanacatib (MK-0822) in men with osteoporosis has completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • odanacatib (odanacatib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2017-12-06